CTI BioPharma (CTIC) PT Hiked to $8 at Needham & Company, Analyst Sees Commercial Success of VONJO with Peak Sales of $595M
Tweet Send to a Friend
Needham & Company analyst Gil Blum raised the price target on CTI BioPharma (NASDAQ: CTIC) to $8.00 (from $5.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
